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Advances in DNA synthesis and assembly methods over
the past decade have made it possible to construct
genome-size fragments from oligonucleotides. Early
work focused on synthesis of small viral genomes,
followed by hierarchical synthesis of wild-type bacterial
genomes and subsequently on transplantation of
synthesized bacterial genomes into closely related
recipient strains. More recently, a synthetic designer
version of yeast Saccharomyces cerevisiae chromosome
III has been generated, with numerous changes from
the wild-type sequence without having an impact on
cell fitness and phenotype, suggesting plasticity of the
yeast genome. A project to generate the first synthetic
yeast genome - the Sc2.0 Project - is currently underway.important practical role, since yeasts are the pre-eminent
organisms for industrial fermentations, with a wide varietyIntroduction
Biology is now undergoing a rapid transition from the
age of deciphering DNA sequence information of the
genomes of biological species to the age of synthetic
genomes. Scientists hope to gain a thorough mastery of
and deeper insights into biological systems by rewriting the
genome, the blueprint of life. This transition demands a
whole new level of biological understanding, which we
currently lack. This knowledge, however, could be obtained
through synthetic genomics and genome engineering,
albeit on a trial and error basis, by redesigning and building
naturally occurring bacterial and eukaryotic genomes whose
sequences are known.
Synthetic genomics arguably began with the report
from Khorana’s laboratory in 1970 of the total synthesis of
the first gene, encoding an artificial yeast alanine tRNA,
from deoxyribonucleotides. Since then, rapid advances in
DNA synthesis techniques, especially over the past decade,
have made it possible to engineer biochemical pathways,* Correspondence: chandra@jhmi.edu
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synthetic organism [1–11]. Genome editing approaches
for genome-wide scale alteration that are not based on
total synthesis of the genome are also being pursued and
have proved powerful; for example, in the production of a
reduced-size genome version of Escherichia coli [4] and
engineering of bacterial genomes to include many different
changes simultaneously [8].
Progress has also been made in synthetic genomics for
eukaryotes. Our group has embarked on the design and
total synthesis of a novel eukaryotic genome structure -
using the well-known model eukaryote Saccharomyces
cerevisiae as the basis for a designer genome, known as
‘Sc2.0’. The availability of a fully synthetic genome will
allow direct testing of evolutionary questions that are
not otherwise approachable. Sc2.0 could also play an
of practical uses, including production of therapeutic
proteins, vaccines and small molecules through classical
and well-developed industrial fermentation technologies.
This article reviews the current status of synthetic
genomics, starting with a historical perspective that
highlights the key milestones in the field (Fig. 1) and
then continuing with a particular emphasis on the total
synthesis of the first functional designer eukaryotic (yeast)
chromosome, synIII, and the Sc2.0 Project. Genome
engineering using nuclease-based genome editing tools
such as zinc finger nucleases, transcription activator-like
effector nucleases and RNA-guided CRISPR-Cas9 is not
within the scope of this minireview (Box 1). Recent
advances in gene synthesis and assembly methods that
have accelerated the genome synthesis efforts are discussed
elsewhere [12].Chemical synthesis of poliovirus cDNA (2002)
Viruses can be viewed as both chemical and ‘living’
entities. Since viral genomes are small, scientists
wondered if it is possible to synthesize an infectious
agent by in vitro chemical-biochemical means solelyarticle distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in
operly credited. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Fig. 1 Timeline of publication milestones for synthetic genomics
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is an enterovirus of the Picornaviridae family and its
sequenced genome comprises a single-stranded RNA
genome of 7.5 kb in length. It replicates naturally in
humans with high efficiency, occasionally causing the
paralyzing and lethal poliomyelitis. The chemical synthesis
of full-length Mahoney poliovirus cDNA wt PV1(M) by
assembling oligonucleotides was first reported by
Cello et al. [13]. The hierarchical strategy for synthesizing
the genome of poliovirus involved three steps: (1) DNA
fragments of 0.4-0.6 kbp length with overlapping comple-
mentary sequences at their termini were produced from
purified oligonucleotides of approximately 70 nucleotides;
(2) the 0.4-0.6 kbp fragments were then ligated into a
plasmid vector to yield three larger DNA segments;
(3) the assembly of a full-length cDNA carrying a phage
T7 RNA polymerase promoter at the 5′ end was achieved
from these three large overlapping DNA segments by
cloning into a plasmid vector, using unique restriction
sites. Several clones were sequenced to identify either the
correct DNA segments or the segments containing small
numbers of errors that could be eliminated, either by
combining the error-free portions of segments by using
an internal cleavage site or by standard site-directed
mutagenesis. Nucleotide substitutions were engineered
into the synthesized viral genome sPV1(M) cDNA as
genetic markers to distinguish it from the wild-type
sequence [13]. De novo synthesis of poliovirus from tran-
script RNA of sPV1(M) cDNA in a cell-free extract of
uninfected HeLa cells indicated that the input synthetic
RNA was translated and replicated in the cell-free extract
and that newly synthesized RNA was encapsulated into
newly synthesized coat proteins, resulting in infectious
poliovirus [13]. This elegant work clearly established that
it was possible to synthesize the genome of an infectious
agent by in vitro chemical-biochemical means based on a
known sequence.
Refactoring bacteriophage T7 (2005)
Evolution by natural selection gives rise to complicated
biological systems that are difficult to understand and
manipulate. Wild-type T7, an obligate lytic phage that
infects E. coli, is one such natural biological system. TheT7 genome comprises a 39,937 bp linear double-stranded
DNA molecule. It is an excellent model organism for
discovering the primary genetic components of a natural
biological system. The 57 genes coding for 60 proteins
have been identified, of which only 35 have a known
function. Of the 25 non-essential proteins, only 12 are con-
served across the T7-like phage family. Driven by a desire
to better understand how the different parts that comprise
bacteriophage T7 work together to encode a functioning
whole, scientists wanted to refactor the genome to a more
structured design that is easy to manipulate and study.
Chan et al. [14] reported the redesign of bacteriophage
T7 by improving its internal structure for future use,
while simultaneously maintaining external system function;
that is, physically separating the primary genetic elements
that are essential for the functioning of the bacteriophage
from the overlapping genetic elements that are non-
essential for the viability of the phage. The T7.1 design
goals were as follows. First, define a set of components that
function during T7 development and for each element
choose an exact DNA sequence to encode the element
function. Second, avoid overlap between DNA sequences
that encode different element functions. Third, assign only
one function to the DNA sequence that encodes each
element. Fourth, incorporate unique restriction sites for
precise and independent manipulation of each element.
Fifth, construct the T7.1 genome. Sixth, refactor the T7.1
genome to encode a viable bacteriophage. Each functional
genetic element was defined, for example, as a promoter,
protein-coding domain, ribosome binding site and so
on. The authors replaced 11,515 bp of the 5′ part of the
39,937 bp wild-type bacteriophage T7 genome with
12,179 bp of engineered DNA using both synthetic DNA
fragments and PCR-amplified T7 fragments, which
contained all genetic elements of the 5′ end plus restric-
tion enzyme sites. The resulting partially synthetic genome
encoded a viable bacteriophage that appeared to maintain
key features of the original while being simpler to model
and making it easier to manipulate each genetic element
encoding a function. This important work established
that large regions of genomes encoding natural bio-
logical systems can be systematically redesigned and
built anew.
Box 1. Genome engineering using programmable
nucleases
Genome engineering by genome-editing tools depends on cellular
responses to targeted chromosomal double-strand breaks (DSBs).
Except for mouse cells, mammalian cells are recalcitrant to gene
targeting [42]. Only one in a million treated cells undergoes
homologous recombination (HR). However, it was discovered
that stimulation of both local mutagenesis and incorporation
of homologous donor sequences can be achieved by generating
targeted DSBs, which was demonstrated most clearly with
rare-cutting endonucleases [43]. The generation of a targeted
DSB remained the rate-limiting step in the development of HR
technology for mammalian cells until the creation of zinc finger
nucleases (ZFNs) by our laboratory, which ushered in the
breakthrough in programmable nucleases [44–47].
ZFNs: the first truly targetable reagents were the ZFNs, which
showed that predetermined DNA sequences could be
addressed for cleavage by protein engineering. ZFNs are formed
by fusing a zinc finger protein (ZFP) that comprises a tandem
array of ZF motifs [48] to the FokI non-specific cleavage domain
[44, 45]. Each ZF motif recognizes a DNA site of 3–4 bp [49].
Studies of the ZFN cleavage mechanism established that the
preferred substrates are inverted repeats [50]. Soon afterwards,
ZFN-induced DSBs were shown to stimulate HR in cells [51–53].
Because ZF motifs interact with and influence the recognition of
their neighbors, the selection methods used to generate highly
specific ZFPs for desired target sites are quite laborious and
time-consuming. The commercial pricing of ZFNs was prohibitively
expensive, putting it beyond the reach of small laboratories.
Transcription activator-like effector nucleases (TALENs): TALENs
are based on the fusion of a different class of DNA-binding
modules, called bacterial transcription activator-like effectors
(TALEs), to the FokI cleavage domain [54]. Each TALE motif
recognizes a single base and appears not to influence the
sequence recognition of its neighbors [55, 56]. Therefore, TALENs
are relatively easier to engineer than ZFNs and they expanded the
targeting capability of programmable nucleases. The fact that
ZFNs and TALENs have been used to modify genomic
sequences of more than 40 different organisms and cell types
attests to the success of this approach to genome engineering.
However, although they are cheaper than ZFNs, the commercial
pricing of TALENs was still too expensive for smaller laboratories.
RNA-guided CRISPR-Cas9: the second technology platform for
inducing a targeted DSB in cellular genomes is the RNA-guided
nucleases (RGNs), which are based on the type II prokaryotic
CRISPR-Cas9 system [57–61]. Unlike ZFNs and TALENs, which use
ZF and TALE motifs, respectively, for DNA sequence recognition,
the CRISPR-Cas9 system depends on RNA-DNA recognition, and its
natural function is to combat invaders of bacteria and archaea,
a testament to nature’s ability to solve problems several ways
(compare restriction enzymes).The advantages of the CRISPR-Cas9
system are its ease of RNA design for new targets; the dependence
on a single, constant Cas9 protein; and the ability to address many
targets simultaneously with multiple guide RNAs. The CRISPR-Cas9
methodology is also very cheap and inexpensive, making it
affordable for small laboratories. These have led to its wide
adoption in research laboratories around the world.
These two technology platforms have equipped scientists with
an unprecedented ability to modify cells and organisms almost
at will, with wide-ranging implications across biology and medicine.
However, both approaches have been shown to cut at off-target
sites, with mutagenic consequences. Therefore, issues like efficacy,
specificity and delivery are likely to drive selection of reagents for
particular purposes. A word of caution about rushing to adopt
CRISPR-Cas9 for human therapeutics and possibly for gene editing
of human embryos: ease of design and use does not necessarily
translate to safety. Therefore, human therapeutic applications of
these technologies ultimately are likely to come down to risk versus
benefit analysis and informed consent.
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clone recombination (2005)
While the smaller viral genomes, such as T7, are amenable
to assembly by standard recombinant DNA techniques
using synthetic or PCR-amplified precursor DNA
fragments (see above), the assembly of larger bacterial
genomes relies on recombination of the precursor DNA
fragments in vivo in a host organism. For this approach to
be successful, one has to be aware of the incompatibilities
between the donor and the recipient host organism.
Studies have shown that microbial genomes can be assem-
bled in only evolutionarily divergent hosts (for example
Synechocystis PCC6803 in Bacillus subtilis, or Mycoplasma
genitalium in S. cerevisiae). In such instances the donor
DNA remains transcriptionally silent without interfering
with the viability of the host. The group of Itaya in Japan
has used this approach to assemble a bacterial genome by
serial integration of precursor DNA fragments directly into
the B. subtilis genome. They cloned almost all of the
3.57 Mbp genome of the donor Synechocystis PCC6803
(a common and highly studied cyanobacterium) as a set of
four separate fragments of approximately 800–900 kbp in
a stepwise serial integration of PCR-generated precursor
DNA fragments into the recipient B. subtilis genome [15].
This work showed that very large non-synthetic constructs
could be produced from bacterial genomic DNA using
in vivo methods. However, the resolution and activation of
the synthetic donor genome is yet to be done.
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the full length mouse mitochondrial and rice chloroplast
genomes from PCR-amplified precursors and recover the
final synthetic DNA product as a circular episome [16].
Similarly, Holt et al. [17] achieved the reassembly of a
fragmented donor genome of Haemophilus influenzae in a
sequential manner into E. coli. This group used lambda
Red recombination, which is an efficient system for E. coli
chromosome engineering that uses electroporated linear
DNA and a defective lambda phage to supply the func-
tions needed for recombination. Using this technique, this
group rebuilt two non-contiguous regions of H. influenzae
genome totaling 190 kbp (approximately 10.4 % of the H.
influenzae genome) as episomes in an E. coli host.
However, both groups found that the bacterial recipient
strains could not tolerate some sections of the donor
genome, such as the rRNA operons and toxic genes.
Chemical synthesis of Mycoplasma genitalium
genome (2008)
The J Craig Venter Institute has pursued complete synthe-
sis and assembly of a whole bacterial (M. genitalium)
genome from chemically synthesized oligonucleotides.
They reported successful synthesis and assembly of a
582,970 bpM. genitalium genome, a culmination of about
10 years of work [5]. In this case, the final complete donor
M. genitalium genome was assembled in the recipient host
S. cerevisiae (yeast). The synthetic genome was essentially
the wild-type M. genitalium G37 sequence except for the
disruption of the gene M408 with an antibiotic marker to
block pathogenicity and allow for selection. A few water-
marks were inserted at intergenic sites in order to identify
the genome as synthetic. The hierarchical synthesis of the
M. genitalium genome was done in three steps: (1) over-
lapping 5–7 kbp DNA fragments were assembled from
chemically synthesized oligonucleotides; (2) the 5–7 kbp
fragments were joined by in vitro recombination to yield
intermediate 24 kbp, 72 kbp and 144 kbp fragments that
were cloned into bacterial artificial chromosomes in E. coli;
(3) the complete synthetic genome was assembled by
homologous recombination in the yeast S. cerevisiae.
Although a clone with the correct sequence was identified,
Gibson et al. [5] did not demonstrate that the synthe-
sized genome encodes a living bacterium. However, in
subsequent work this was shown by the same group for a
synthesized Mycoplasma mycoides genome (below) [10].
This impressive work established that chromosome-size
DNA molecules could be constructed from chemically
synthesized pieces.
Synthesis and assembly of the Mycoplasma
mycoides genome (2010)
Subsequently, Gibson et al. [10] reported the creation of
a bacterial cell controlled by a chemically synthesizedgenome. A 1.08 Mbp M. mycoides genome was synthesized
from known genome sequence; it was then transplanted
into a closely related Mycoplasma capricolum recipient cell
to form a new M. mycoides cell that was controlled solely
by the synthetic genome. The chemically synthesized
genome had several alterations compared with the
wild-type CP001668, which included four watermark
sequences, a designed 4 kbp gene deletion and nucleotide
polymorphisms at 20 locations, 19 of which were from
harmless mutations acquired during the assembly process.
These 19 sequence alterations also served as polymorphic
differences between the synthetic genome and the wild-
type genome. The newly created cell had the expected
phenotypic properties of M. mycoides and was capable of
continuous self-replication [10].
The synthetic M. mycoides genome was assembled
from 1,078 overlapping DNA cassettes in three steps: (1)
DNA fragments of 1,080 bp, which were produced
from overlapping synthetic oligonucleotides, were
combined to form 109 larger DNA fragments of about
10 kbp; (2) these were then recombined in pools of
10 to create 11 DNA segments of about 100 kbp in
length; (3) the 11 segments were recombined to form
the complete M. mycoides genome. All assemblies were
carried out by in vivo homologous recombination in
yeast, except for two constructs that were enzymati-
cally pieced together in vitro. The designed sequence
was 1,077,947 bp in length.
The study also showed that a single base pair deletion in
the essential gene dnaA could render the synthetic M.
mycoides genome inactive, whereas large genome insertions
and deletions in non-essential parts of the genome had no
observable effect on viability. This foundational work
provided a proof-of-principle experiment for producing
cells based on computer-designed genome sequences,
even though the synthetic genome had only very limited
modifications from the naturally occurring M. mycoides
genome.
Minimal bacterial genome
The vast differences that exist in the genome sizes of
bacterial species begs the question, ‘What is the minimal
set of genes or the minimal genome [18] that is needed
for cellular life?’ A corollary to this question is, ‘What is
the minimal set of genes shared by all bacterial species
through evolution?’ Using gene deletion methods, several
groups have successfully produced smaller and increasingly
stable, streamlined bacterial genomes. These studies, using
what is known as the top-down approach, have shown that
large proportions of bacterial genomes can be deleted
without any major growth defects. Research on E. coli
laboratory strain MDS42 has shown that almost
15.3 % of the genome could be eliminated without affect-
ing its growth characteristics [4, 19, 20]. The deleted genes
Annaluru et al. Genome Biology  (2015) 16:125 Page 5 of 12include the transposable elements and horizontally de-
rived genes that have important roles under special
environmental conditions. Further work has shown
that as much as 22 % of the MDS42 genome could
be eliminated without any major growth defects. Other
groups have also reported successful genome reduction
efforts in Schizosaccharomyces pombe, B. subtilis and
E. coli [21–23].
M. genitalium is a bacterium with the smallest genome
of any independently replicating cell; it encodes 485
protein coding genes of which 100 are non-essential when
individually disrupted. The small size of mycoplasma
genomes makes them a prime candidate for creating a
minimal genome using the bottom-up approach of
synthetic genomics [5]. The J Craig Venter Institute is
working towards a minimal mycoplasma genome by
exploring whether genes that can be disrupted individually
without affecting the fitness could also be deleted glo-
bally. De novo genome synthesis offers the ability toFig. 2 Multiplex automated genome engineering (MAGE) and conjugative
more details) to replace all TAG codons with TAA in E. coli. b Use of CAGE
recipient (R) genome. oriT in the donor genome serves as the transfer initiasimultaneously implement many directed changes to
the natural genome by building and testing a variety
of reduced genomes by genome transplantation in a
closely related host strain. The bottom-up approach
should make it possible to arrive at the minimal
mycoplasma genome that enables cellular life.
Expanding the genetic code of E. coli (2013)
Church, Isaacs and colleagues have used other genome-
editing methods to alter the genetic code on a genome-
wide scale in E. coli, thereby rewriting the genetic program.
One approach, multiplex automated genome engineering
(MAGE), allows for introduction of multiply targeted,
small mutations through oligonucleotide-directed allelic
replacement in an iterative manner (Fig. 2a; refer to [8] for
more details). A second technique, conjugative assembly
genome engineering (CAGE), allows for step-wise transfer
of individually engineered genomic modules into a
single genome (Fig. 2b; refer to [24] for more details).assembly genome engineering (CAGE). a Use of MAGE (refer to [8] for
(refer to [24] for more details) to incorporate a donor (D) into a
tion point
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construct a recoded E. coli genome with an expanded
genetic code [8, 24]. The translation-termination of the
three stop codons (TAG, TAA and TGA) of the E. coli
genetic code is mediated by two release factors, RF1 and
RF2. RF1 recognizes the termination codons TAA and
TAG, whereas RF2 recognizes TAA and TGA. The
authors reasoned that replacing all TAG codons with
synonymous TAA codons would abolish genetic de-
pendence on RF1 and permit the newly reassigned
TAA codons to be recognized by RF2. After removal
of all genomic TAG codons, the prfA gene that codes
for release factor 1 (RF1) was deleted. The authors
hypothesized that this would enable them to test and
leverage the redundancy of the genetic code and to pro-
vide a blank TAG codon that could be cleanly reassigned
to a new function. The TAG codon was reintroduced
along with an orthogonal set of aminoacyl-tRNA synthase
and tRNA to encode a non-standard amino acid. The
engineered E. coli incorporated non-standard amino acids
into its proteins and showed enhanced resistance to
bacteriophage T7 [25]. The Church group also recoded 13
codons in 42 highly expressed essential genes in E.
coli, indicating that codon usage is quite flexible [26].
Recently, two laboratories have redesigned essential
enzymes of E. coli with an altered genetic code by
changing TAG codons to TAA. This confers meta-
bolic dependence on non-standard amino acids for
survival as a means for biocontainment of genetically
modified organisms [27, 28].
The first synthetic designer eukaryotic
chromosome (2014)
The idea for designing and synthesizing a eukaryotic
chromosome was initiated by our group in collaboration
with Jef Boeke in 2005. The concept for hierarchically
synthesizing a designer yeast chromosome was quite
simple. First, design the synthetic chromosome incorpor-
ating all the desired changes based on the available
wild-type chromosome sequence of S. cerevisiae. Second,
compile the designed chromosome into pieces of about
10 kbp by including unique restriction sites at the 5′
and 3′ ends to enable further ligation of the 10 kbp
pieces into segments of about 30–50 kbp. Synthesize
these pieces of about 10 kbp using oligonucleotides
from commercial vendors. Third, as yeast is highly
recombinogenic, use an iterative strategy with alter-
nating genetic markers to replace each 30–50 kbp
segment of the wild-type sequence with the corresponding
synthetic pieces, one at a time by homologous recom-
bination in vivo in yeast.
The initial proof-of-principle experiment was performed
in our laboratory by first designing and synthesizing a
30 kbp fragment of yeast chromosome III and thenreplacing the wild-type segment with the synthetic
piece in yeast [29]. By 2007, the idea of synthesizing
a eukaryotic chromosome had morphed into an ambi-
tious project with the goal of rewriting wild-type S.
cerevisiae Sc1.0 into a synthetic version, Sc2.0.Design principles for the synthetic yeast genome (Sc2.0)
Suggestions for the types of changes to be incorpo-
rated into Sc2.0 were obtained by Boeke from the
community of yeast researchers. Only conservative changes
were included, as more drastic changes might result
in ‘dead’ yeast. The synthetic yeast should have the
same fitness as the wild type and grow normally; this
is an obvious minimal requirement for Sc2.0. The
three design principles for the synthetic yeast genome
are as follows: (1) it should result in a (near) wild-
type phenotype and fitness; (2) it should lack destabil-
izing elements to avoid the synthetic yeast genome
from being unstable or undergoing rearrangements;
(3) it should have genetic flexibility to facilitate future
studies [30].
How does one design a Sc2.0 genome that will facili-
tate future studies? Yeast contains about 6000 genes and
almost 5000 of these are non-essential when disrupted
individually [31]. As such, all the non-essential genes
were flanked with loxPsym sites. Once a synthetic
chromosome or the Sc2.0 genome is built, in theory,
one could expose the synthetic yeast strains to Cre
recombinase for various time intervals and look for
survivors. PCR-Tag analysis (see synIII construction)
and sequencing of the genomes of survivors would
reveal what combinations of non-essential genes have
been deleted from the starting Sc2.0 genome, leaving
the survivors viable.synIII design
After a successful proof-of-principle experiment involv-
ing the design of a synthetic 30 kbp chromosome III
fragment that was used to replace the native sequence in
yeast, the sequence of the whole native chromosome III
was edited in silico using Biostudio [32] to incorporate a
series of deletions, insertions and base substitution
changes to produce the desired ‘designer’ sequence (Box 2
and Fig. 3a). The synthetic version of chromosome III
(known as synIII) also encodes a built-in recombination
system called SCRaMbLE (synthetic chromosome re-
arrangement and modification by loxP-mediated evolu-
tion) to enable removal of the non-essential parts of the
chromosome, and therefore streamline it, by inducing
genomic alterations of the synIII strain using Cre recom-
binase [32]. As the result of these alterations, synIII
(272,871 bp) is about 13.8 % smaller than the native
chromosome III (316,667 bp) [32].
Box 2. Modifications in synIII chromosome
 Elements removed: 10 transfer RNA genes, 21 Ty elements
and/or derived long terminal repeats (LTRs), 7 introns, the
silent mating loci HML and HMR, and subtelomeric
sequences lying to the left of YCL073C and the right of
YCR098C were removed [32]
 Elements relocated to extrachromosomal array: a single copy
tRNA gene, SUP61, which codes for tRNASer (CGA) is
essential to the yeast cell. Therefore, it was encoded in trans
on a centromeric plasmid, which allowed deletion of the
gene from synIII chromosome [32]
 Elements replaced: (1) TAG stop codons were replaced by
TAA. Removal of the TAG stop codons from the synthetic
genome will allow future genetic code manipulation [32].
(2) The telomeres were specified by a minimal ‘universal
telomere cap’ comprising 305 bp of T(G)1–3 sequence.
(3) Single synonymous codons were used to incorporate
unique restriction sites (or delete sites) to facilitate synIII
assembly. (4) Short stretches of synonymous codons
(fewer than ten codons) were recoded to generate
‘PCR-Tags’ that serve as the basis for PCR primer design
[30]. PCR-Tags are used to distinguish wild-type from
synthetic sequence by selective PCR amplification
 Elements introduced: symmetrical loxP (loxPsym) sites were
inserted in the 3′ UTR of all non-essential genes as well
as at synthetic landmarks such as sites of LTR and tRNA
deletion or flanking the centromere [32]. loxPsym sites lack
the directionality of canonical loxP Cre recombinase sites
and can align in two orientations. Therefore, both inversions
and deletions are possible during SCRaMbLE using Cre
recombinase [30]
 Elements not changed: gene order was preserved in synIII to
prevent incorporation of a non-permissible configuration
[32]. Induction of SCRaMbLE results in changes in gene
order and chromosome structure [30]. All recovered
SCRaMbLEd yeasts will have viable genome structures
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The hierarchical workflow that was used to construct
synIII (Fig. 3b) consisted of three major steps. In the
first step, the 750 bp ‘building blocks’ (BBs) were pro-
duced starting from overlapping 60-mer to 79-mer
oligonucleotides and assembled using standard PCR
methods [33]. In a second step, the BBs were assembled
into overlapping DNA ‘minichunks’ of approximately
2–4 kb using either the uracil-specific excision reaction[34] or cloning into a shuttle vector by homologous re-
combination in yeast S. cerevisiae [35–39]. In the USER
approach, four to five BBs are used that each have a
5–13 bp sequence of the type A(N)3 T to A(N)11 T
that overlaps with their adjoining neighbors and a
vector. These BBs are amplified using forward and
reverse primers containing a single uracil instead of
the T and are then treated with USER enzymes (a
mixture of uracil DNA glycosylase and the DNA
glycosylase-lyase endonuclease VIII) to generate com-
plementary single-stranded ends. The BBs are then
ligated and cloned into E. coli to recover recombinants
containing the assembled ‘minichunks’. The yeast
homologous recombination cloning approach is much
simpler, where four to five BBs each with 40 bp over-
laps with their adjoining neighbors are assembled
into a shuttle vector by direct transformation into
the highly recombinogenic S. cerevisiae. This approach
obviates the need for another round of PCR amplifi-
cation of the BBs using primers containing uracil and
the use of USER enzymes. Thus, as it turns out, all
you need is yeast for minichunk assembly. In the
third and final step, the adjacent minichunks for
synIII were designed to overlap one another by one
BB to facilitate further assembly in vivo by homolo-
gous recombination in yeast. Using an average of 12
minichunks and alternating selectable markers in
each experiment, the native sequence of S. cerevisiae
III was systematically replaced by its synIII counter-
part in 11 successive rounds of transformation. PCR-
Tag analysis (Fig. 4) and sequencing confirmed the
identity of synIII [32]. The fact that the numerous
design changes to the DNA sequence of the chromo-
some III had little or no impact on cell fitness and
phenotype suggests the very pliable nature of the yeast
genome [32].
International consortium to synthesize the Sc2.0 genome
A group of international scientists has taken up the
synthesis of the Sc2.0 genome. The Beijing Genome
Institute in China was the first to agree to synthesize
four of the yeast chromosomes. Since then laboratories
from various other countries have also joined the Sc2.0
effort to synthesize the remaining yeast chromosomes.
Each participating laboratory is required to sign an
Agreement with Johns Hopkins University (now with
New York University). This arrangement leaves the
control of the Sc2.0 project to Boeke, who is a yeast
expert. Such a central organization is needed for the
coordination of a huge undertaking such as Sc2.0 and for
the distribution of yeast strains, reagents and experimental
protocols. Participating laboratories have to raise their
own funds from their own country to synthesize the
allotted chromosome.
ab
Fig. 3 synIII design and synthesis. a synIII design. Twenty-one retrotransposons (RT) and seven introns were removed. Forty-three TAG stop
codons were changed to TAA stop codons. Ninety-eight loxPsym sites were introduced to enable SCRaMbLE analysis. The two natural telomeres
were replaced with shorter universal telomere caps. A single copy of essential tRNA gene SUP61, which codes for tRNASer (CGA), was deleted
and moved to a tRNA neochromosome. Numerous PCR-Tags were incorporated into synIII to distinguish it from the natural counterpart. As a
result, synIII is about 13.8 % smaller than the native yeast chromosome III (Box 2). For the complete set of additions, deletions and other genome
modifications to synIII, see Annaluru et al. [32]. b synIII synthesis. synIII was constructed in three steps (shown in the flow diagram on the left, from
bottom to top). In step 1, 750 bp building blocks (BB) were synthesized from 60-mer oligonucleotides at Johns Hopkins University by undergraduate
students in the Build-A-Genome course [33]. In step 2, three to five BB were assembled into 2–4 kb minichunks by homologous recombination
in Saccharomyces cerevisiae [35]. Adjacent minichunks were designed to encode overlap of one BB to facilitate downstream assembly. In step 3, direct
replacement of native yeast chromosome III with pools of synthetic minichunks was performed. Eleven iterative one-step assemblies and replacements
of native genomic segments of yeast chromosome III were carried out using pools of overlapping synthetic DNA minichunks, encoding alternating
genetic markers (LEU2 or URA3), which enabled complete replacement of native III with synIII in yeast [32]. The number of oligonucleotides, BBs, and
minichunks needed to construct synIII are shown in parentheses. SynIII is 272,871 bp long, compared with the 316,667 bp long native yeast
chromosome III
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The synIII chromosome is about 2.5 % of the yeast
genome and the changes that were made were all
conservative, although numerous. These sequence
alterations have not reduced the fitness of the yeast,
which is encouraging in terms of the potential for
future modifications. There are about 98 loxPsym
sites in synIII, which scales to about 4000 loxPsym
sites for the entire Sc2.0 genome. It is not yet clear
how all of these loxPsym sites along with all the
other modifications will ultimately affect the stability
of the Sc2.0 genome and the viability of the syntheticyeast cell. The results from synIII are encouraging
and the synthesis of a few more chromosomes will
give us a better idea. Boeke’s laboratory is working on the
assembly of the synVI chromosome using fragments
of approximately 10 kbp from commercial vendors.
Our laboratory is in the process of completing the assem-
bly of the synIX chromosome. With the experience gained
from the synthesis and assembly of synIII, we estimate that
the construction of a chromosome about 1 Mbp could be
done in 2–3 years.
Once the Sc2.0 genome is built, an important focus
will be to determine the minimal eukaryotic (yeast)
Fig. 4 PCR-Tag analysis of a synIII segment. a The YCL061C.3 locus-specific PCR-Tag forward (F) and reverse (R) primers for the wild type (WT)
and synIII are shown. The changes between the two are shaded. PCR-Tags are short pairs of recoded segments used as genetic markers to verify
introduction of a synthetic sequence and removal of native sequence. Pairs of 25–28 bp sequences about 500 bp apart were recoded with
synonymous codons such that >33 % of the bases were changed; the first and last base PCR-Tag primers were coded to be different between
the WT and synIII sequences. b Agarose gel profiles of PCR-Tag analysis of a WT DNA segment and the corresponding synthetic synIII segment
(YCL061C.3 to YCL050C.1). A virtual gel image was generated using LabChip GX software version 4.0.1418.0
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can one be deleted? Which combinations of the 5000
yeast non-essential genes that are dispensable individually
can be simultaneously removed? If we possess this
knowledge, we will be able to achieve further reduction in
the size of the Sc2.0 chromosomes and the genome. The
plan is to use SCRaMbLE analysis to arrive at the minimal
yeast genome (Fig. 5). This approach involves exposing
Sc2.0 to Cre recombinase for various time intervals and
looking for survivors. We reason that PCRTag analysis
and sequencing the genomes of the survivors would reveal
what combinations of non-essential genes have been
deleted from the starting synthetic genome, leaving
the survivors viable.
This pathway to the minimal yeast genome would
represent a ‘top down’ approach since we start from
the entire newly designed Sc2.0 genome and progres-
sively delete increasing parts of the genome. However,
to complicate matters, the essential and non-essential
genes of the synthetic yeast are interspersed with one
another. Because of this intertwining, SCRaMbLEing
of the Sc2.0 is likely to result in dead yeast most of
the time. Only yeasts with small deletions are likely
to survive, making it difficult to deduce the minimal
genome. Furthermore, due to the inherent symmetry
of loxPsym sites, when two such sites are broughttogether by a Cre recombinase, it could result in an
insertion, a deletion, an inversion or a translocation
(Fig. 3). Moreover, there is also the possibility of
interchromosomal rearrangements through the loxPsym
sites, in addition to the expected intrachromosomal
deletions, inversions, insertions and rearrangements.
Analysis of such widely variant genomes from a popula-
tion of survivors would involve time-consuming costly
experimentation and complicated data analysis to decipher
the minimal yeast genome. This hurdle could be overcome
to some extent by performing SCRaMbLE analysis at
the level of intermediate yeast strains, each possessing
an individual synthetic chromosome. Thus, one could
delineate a set of 16 minimal chromosomes for yeast.
All of the reduced yeast chromosomes could then be
combined into a final yeast strain to form a minimal
eukaryotic genome.
Conclusions and future perspectives
Recent literature reports make it clear that entire
chromosomes and genomes can be designed, synthesized
and incorporated into cells to produce synthetic organisms.
However, to create a truly living, dividing synthetic cell
from scratch by de novo synthesis, we need to know the
minimal set of essential genes required for life and
have a clear understanding of how each gene functions,
Fig. 5 Synthetic chromosome rearrangement and modification by loxP-mediated evolution (SCRaMbLE) of the synIII strain. Examples of inversion,
translocation and deletion products resulting from Cre recombinase treatment of synIII strain are shown
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needed for harmonious gene function. It is very likely that
the research on Mycoplasma, which have the smallest
genomes among free-living cellular organisms, will be
the first to lead to the delineation of the minimal set
of genes required for life; this will be achieved either
through stepwise iterative deletion of nonessential
genes [40] or by de novo synthesis of several arbitrarily
reduced genomes.
An international consortium of scientists is now
working to synthesize the remaining 15 chromosomes
of the yeast Sc2.0 genome, a model eukaryote. At this
juncture, the best that one can say about Sc2.0 is that
we are trying to rewrite Sc1.0 to Sc2.0, albeit with
numerous conservative changes. The main stated purpose
for designing and engineering of Sc2.0 is to improve our
understanding of the evolution of eukaryotic genome
structure and function.
Can the design rules be successfully applied across
the entire yeast genome? Is the Sc2.0 genome worth
doing? What are the potential industrial applications
of Sc2.0? These are difficult questions to answer at
this juncture. However, there is a critical need to develop
alternative yeast strains as ‘chassis’ organisms for the pro-
duction of pharmacologically important compounds suchas artemisinin [41]. Will the ‘streamlined’ yeast strains
resulting from in vitro evolution of the Sc2.0 genome be
useful in this regard? Only time will tell. The total
synthesis of a functional designer yeast chromosome
represents an important milestone for eukaryotic synthetic
biology. synIII work paves the way for other future syn-
thetic genomics projects that seek to rewrite animal or
plant chromosomes and genomes using specific design
principles. The DNA synthesis technology and the
genome engineering tools needed for such a major
undertaking are currently available to scientists. However,
it is too early to speculate about a minimal eukaryotic
genome at this juncture.
In conclusion, recent breakthroughs in synthetic
genomics have ushered in a new era for synthetic
biology with the real potential to create a truly man-made
living and dividing synthetic cell.
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